Identification of key genes and molecular pathways in type 2 diabetes mellitus and polycystic ovary syndrome via bioinformatics analyses.
暂无分享,去创建一个
[1] Jingyun Wang,et al. Discovery of immune-related diagnostic biomarkers and construction of diagnostic model in varies polycystic ovary syndrome , 2022, Archives of Gynecology and Obstetrics.
[2] J. Olefsky,et al. Inflammation in obesity, diabetes, and related disorders. , 2022, Immunity.
[3] Rafael Riudavets Puig,et al. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles , 2021, Nucleic Acids Res..
[4] K. Baek,et al. Pathogenetic analysis of polycystic ovary syndrome from the perspective of omics. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[5] Qi Yu,et al. Downregulating lncRNA NEAT1 induces proliferation and represses apoptosis of ovarian granulosa cells in polycystic ovary syndrome via microRNA-381/IGF1 axis , 2021, Journal of biomedical science.
[6] Zi-jiang Chen,et al. Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome , 2021, Microbiome.
[7] Yan Jin,et al. Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes , 2021, Journal of extracellular vesicles.
[8] A. Duszewska,et al. Chronic Low Grade Inflammation in Pathogenesis of PCOS , 2021, International journal of molecular sciences.
[9] J. Qiao,et al. The impact of the gut microbiota on the reproductive and metabolic endocrine system , 2021, Gut microbes.
[10] Lin Cheng,et al. Gene Expression Profiling of Type 2 Diabetes Mellitus by Bioinformatics Analysis , 2020, Comput. Math. Methods Medicine.
[11] M. Nieuwdorp,et al. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes , 2020, Frontiers in Immunology.
[12] A. Aversa,et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions , 2020, Frontiers in Endocrinology.
[13] R. Ruslami,et al. Type 2 Diabetes and its Impact on the Immune System , 2020, Current diabetes reviews.
[14] H. Yi,et al. Immunophenotypic Profiles in Polycystic Ovary Syndrome , 2020, Mediators of inflammation.
[15] Kai-Lee Wang,et al. Disturbed Gastrointestinal Contractility in a Polycystic Ovary Syndrome Rat Model , 2020, Digestive Diseases and Sciences.
[16] S. Basit,et al. Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives , 2019, The application of clinical genetics.
[17] C. Ling,et al. Epigenetics in Human Obesity and Type 2 Diabetes , 2019, Cell metabolism.
[18] X. Bi,et al. Identification of the key pathways and genes related to polycystic ovary syndrome using bioinformatics analysis. , 2019, General physiology and biophysics.
[19] M. Prentki,et al. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift , 2019, Diabetes & vascular disease research.
[20] Seema Patel. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy , 2018, The Journal of Steroid Biochemistry and Molecular Biology.
[21] D. Briscoe,et al. DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. , 2018, Physiological reviews.
[22] B. Tarlatzis,et al. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. , 2017, Metabolism: clinical and experimental.
[23] L. Ruilope,et al. Investigational calcium channel blockers for the treatment of hypertension , 2016, Expert opinion on investigational drugs.
[24] Núria Queralt-Rosinach,et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants , 2016, Nucleic Acids Res..
[25] T. Tomita. Apoptosis in pancreatic β-islet cells in Type 2 diabetes. , 2016, Bosnian journal of basic medical sciences.
[26] F. Petraglia,et al. Genetic, hormonal and metabolic aspects of PCOS: an update , 2016, Reproductive Biology and Endocrinology.
[27] P. Spritzer,et al. Effects of orlistat vs. metformin on weight loss‐related clinical variables in women with PCOS: systematic review and meta‐analysis , 2016, International journal of clinical practice.
[28] G. Pacini,et al. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus , 2016, Endocrine reviews.
[29] H. Kaneto. [Pathophysiology of type 2 diabetes mellitus]. , 2015, Nihon rinsho. Japanese journal of clinical medicine.
[30] Fan Shen,et al. A Double Heterozygous Mutation of TNNI3 Causes Hypertrophic Cardiomyopathy in a Han Chinese Family , 2015, Cardiology.
[31] K. Taguchi,et al. G-protein-coupled receptor kinase 2 and endothelial dysfunction: molecular insights and pathophysiological mechanisms , 2015, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.
[32] Byung-Cheol Lee,et al. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. , 2014, Biochimica et biophysica acta.
[33] H. Kobori,et al. Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice , 2013, PloS one.
[34] Frédéric Schütz,et al. HCFC1 is a common component of active human CpG-island promoters and coincides with ZNF143, THAP11, YY1, and GABP transcription factor occupancy , 2013, Genome research.
[35] E. Diamanti-Kandarakis,et al. Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. , 2013, European journal of endocrinology.
[36] Y. Liu,et al. Evaluation of the association between the ADRA2A genetic polymorphisms and type 2 diabetes in a Chinese Han population. , 2012, Genetic testing and molecular biomarkers.
[37] W. Lieberthal,et al. Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. , 2012, American journal of physiology. Renal physiology.
[38] M. Fernandez,et al. Inflammation and type 2 diabetes. , 2012, Diabetes & metabolism.
[39] K. Inoki,et al. AMPK and mTOR in cellular energy homeostasis and drug targets. , 2012, Annual review of pharmacology and toxicology.
[40] Tom R. Gaunt,et al. Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies , 2011, Diabetologia.
[41] J. Potter,et al. Cardiac Troponin Mutations and Restrictive Cardiomyopathy , 2010, Journal of biomedicine & biotechnology.
[42] S. Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[43] V. Chalifa-Caspi,et al. Gene expression microarray profiles of cumulus cells in lean and overweight-obese polycystic ovary syndrome patients. , 2008, Molecular human reproduction.
[44] A. Halpern,et al. Orlistat in the prevention of diabetes in the obese patient , 2008, Vascular health and risk management.
[45] S. Elmore. Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.
[46] U. Boggi,et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. , 2002, Diabetes.
[47] A. Grossman,et al. Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man. , 1994, The Journal of endocrinology.
[48] Maysson Ibrahim,et al. Pathways Enrichment Analysis of Gene Expression Data in Type 2 Diabetes. , 2020, Methods in molecular biology.
[49] L. Igel,et al. Obesity Pharmacotherapy. , 2018, The Medical clinics of North America.
[50] D. Vučić,et al. Intracellular regulation of TNF activity in health and disease. , 2018, Cytokine.
[51] S. Recabarren,et al. [Epigenetics of polycystic ovary syndrome]. , 2017, Revista medica de Chile.
[52] W. Kerner,et al. Definition, classification and diagnosis of diabetes mellitus. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[53] P. Anagnostis. Metabolic syndrome in the Mediterranean region: Current status , 2012, Indian journal of endocrinology and metabolism.
[54] Karin Kraft,et al. [Type-2 diabetes]. , 2010, MMW Fortschritte der Medizin.